{"organizations": [], "uuid": "ea737e826432ca9fb63cbb8c03fa9c62e61ef4cd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-xenon-presents-positive-xen1101-tm/brief-xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-data-at-14th-eilat-conference-idUSFWN1SM0PD", "country": "US", "domain_rank": 408, "title": "BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.011, "site_type": "news", "published": "2018-05-15T18:14:00.000+03:00", "replies_count": 0, "uuid": "ea737e826432ca9fb63cbb8c03fa9c62e61ef4cd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-xenon-presents-positive-xen1101-tm/brief-xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-data-at-14th-eilat-conference-idUSFWN1SM0PD", "ord_in_thread": 0, "title": "BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "xenon pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "tms", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE\n* XENON PHARMACEUTICALS INC - INITIATED A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CROSS-OVER PHASE 1B TMS STUDY\n* XENON PHARMACEUTICALS INC - PHASE 1B TMS STUDY DATA EXPECTED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T18:14:00.000+03:00", "crawled": "2018-05-16T19:22:06.000+03:00", "highlightTitle": ""}